

# 20. Mitteilungsblatt

## Nr. 28

Mitteilungsblatt der Medizinischen Universität Wien  
Studienjahr 2021/2022  
20. Stück; Nr. 28

Bevollmächtigungen

28. Bevollmächtigungen gem. § 27 Abs. 2 UG

## 28. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitle	Organisationseinheit	Projektleiter(in)
FA731E0607	A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letemovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients	Allgemeinchirurgie_73 1	Berlakovich Gabriela
FA731E0608	Evaluating CYP3A function after orthotopic liver transplantation using a microdose of midazolam as a marker substance	Allgemeinchirurgie_73 1	Berlakovich Gabriela
FA731E0610	Liver transplantation in patients with Cirrhosis and severe Acute-on-Chronic Liver Failure (ACLF): indications and outcomes (CHANCE) Study	Allgemeinchirurgie_73 1	Berlakovich Gabriela
FA731E0701	The impact of iron homeostasis on liver regeneration - a pilot study	Allgemeinchirurgie_73 1	Schwarz Christoph
FA738A1303	Klinischen Prüfung der pharmakologische Sicherheit und Wirksamkeit des Prüfpräparates AP301 powder for reconstitution for solution for inhalation in Patienten mit pulmonalem Permeabilitätsödem bei Patienten mit mäßigem bis schwerem akutem Atemnotsyndrom (ARDS)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina

FA738A1304	Prospektive, randomisierte Studie zur Personalisierten Medizin mit Pentaglobin nach einer interventionellen Fokussanierung bei Peritonitis-Patienten	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1307	Hinweisgestütztes Beatmungsmanagement zur Verhinderung des Akuten Lungenversagens - ALARM Studie	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Burger-Klepp Ursula
FA738A1308	Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Phase 2a/b clinical trial	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1308	Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Phase 2a/b clinical trial	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1309	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1310	ALT00 Pilot	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1602	Treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Baron David

FA738A2101	Feasibility of a neuromuscular electrostimulation device for mechanical thromboprophylaxis in ICU patients	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Wiegele Marion
FA738A2201	Monitoring der Herzratenvariabilität in der perioperativen Phase	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Klein Klaus Ulrich
FA738A2401	19-515 "Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Require Urgent Surgery	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Gratz Johannes
FA738A2901	Ultrasound assessment of gastric emptying after a standardized high calorie liquid meal: a pilot study in healthy adults	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Bologheanu Razvan
FA738C1001	Safe and Timely Antithrombotic Removal (STAR): International registry on the use of CytoSorb for removal of antithrombotic agents in the acute hospital setting	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Bernardi Martin Hermann
FA613A0501	Zukunftskolleg ZK 57-B28	Anatomie und Zellbiologie_310	Vesely Cornelia
FA746A0267	YOSEMITE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0268	RHINE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

	AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA		
FA746A0272	A 64-week,two-arm,random.,dbl-masked, multicenter,phase IIIb study assessing the efficacy and safety of brolocizumab 6 mg comp. to aflibercept 2 mg in a treat-to-control regimen in patients with nAMD	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0272	A 64-week,two-arm,random.,dbl-masked, multicenter,phase IIIb study assessing the efficacy and safety of brolocizumab 6 mg comp. to aflibercept 2 mg in a treat-to-control regimen in patients with nAMD	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0275	A one-year, single-arm, open-label, multicenter study assessing the anatomic outcomes of brolocizumab assessed by OCT-A in adult patients with neovascular age related macular degeneration	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A1506	Unrestricted Grant - Single-capture widefield (WF) optical coherence tomography angiography (OCTA) for detection of retinal perfusion and neovascularization in eyes of diabetic patients	Augenheilkunde und Optometrie_746	Pollreiz Andreas

FA746A1642	Unrestricted Grant - Untersuchung der funktionellen und morphologischen Langzeit-Auswirkungen der Chorioretinopathia centralis serosa (CCS) über einen Zeitraum von 10 Jahren	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2505	Post-hoc imaging review for detection of potential imaging signs of inflammation	Augenheilkunde und Optometrie_746	Gerendas Bianca
FA746A2607	A randomized, double- blind, placebo- controlled, 12-month phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treatment-naïve or untreated for at least 6 months	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A3601	Annotation Service Agreement	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA746A3602	Research Collaboration Agreement between RetInSight GmbH - Medical University of Vienna regarding phd studies	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA662A0403	MG-Mitralring	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0502	GESUNDHEIT IN BEWEGUNG - Gesundheit von morgen erforschen und entwickeln	Biomedizinische Forschung_308	Kramer Anne- Margarethe
FA662A0503	"In vivo study of a compliant graft material for treatment for the treatment of aortic disease"	Biomedizinische Forschung_308	Kramer Anne- Margarethe

FA727A0616	A pivotal Phase II randomised, multicentre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-Cell Lymphoma (R-R DLBCL)	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
FA722A0403	Single cell analysis from skin of volunteers of 2 different age groups	Dermatologie_722	Tschachler Erwin
FA722A0601	Protecting vascular barrier function across discipline and disease boundaries	Dermatologie_722	Schossleitner Klaudia
FA722B1138	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma (RELATIVITY 098)	Dermatologie_722	Höller Christoph
FA722C1209	A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis.	Dermatologie_722	Kinaciyar Tamar
FA722C1210	Durchführung der HAE Survey Patientenpräferenz	Dermatologie_722	Kinaciyar Tamar
FA722C1414	Abrocitinib expanded access protocol for the treatment of adolescents and adults with moderate to severe atopic dermatitis.	Dermatologie_722	Bangert Christine

FA751B0109	A multicenter, prospective, observational study to evaluate the use of the sFlt-1/PlGF ratio in the risk stratification of pregnant women with signs and symptoms of preeclampsia or diagnosed preeclampsia in current clinical practice	Frauenheilkunde_751	Zeisler Harald
FA751C0135	An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO Sponsored Niraparib Study and are Judged by the Investigator to Benefit from Continued Treatment with Niraparib	Frauenheilkunde_751	Reinhaller Alexander
FA751C0211	Tumor Suppressor Protein Aggregation Determines Response to Olaparib	Frauenheilkunde_751	Zeillinger Robert
FA751C0518	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	Frauenheilkunde_751	Wenzl René
FA751C0662	Germline BRCAness in patients with ovarian and breast cancer with and without family history	Frauenheilkunde_751	Singer Christian



FA751C0672	Doppelblinde, randomisierte Phase-III-Prüfung zur Bewertung einer Umstellung auf AZD9833 (oralen SERD der nächsten Generation) + CDK4/6-Inhibitor (Palbociclib oder Abemaciclib) im Vergleich zu einer Fortsetzung der Behandlung mit einem Aromatasehemmer (Letrozol oder Anastrozol) + CDK4/6-Inhibitor bei Patienten mit HR positivem/HER2-negativem metastasierten Mammakarzinom und Nachweis einer ESR1-Mutation ohne Krankheitsprogression während der Erstlinientherapie mit einem Aromatasehemmer + CDK4/6-Inhibitor – ctDNA-gesteuerte Prüfung zur frühen Therapieumstellung	Frauenheilkunde_751	Singer Christian
FA751C0673	Randomisierte, doppelblinde Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Niraparib mit Placebo bei Teilnehmerinnen mit HER2-negativem BRCA-mutierten oder mit triple-negativem Mammakarzinom mit Molekularkrankheit basierend auf dem Vorliegen von zirkulierender Tumor-DNA nach einer definitiven Therapie.	Frauenheilkunde_751	Singer Christian

FA751C0674	A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy	Frauenheilkunde_751	Singer Christian
FA751C0702	Early Detection of Ovarian Cancer using Uterine Lavage and Duplex Sequencing	Frauenheilkunde_751	Speiser Paul
FA751C1207	PD-L1 heterogeneity in primary and matched metastatic lesions in TNBC and HER2-enriched breast cancers	Frauenheilkunde_751	Pfeiler Georg
FA751C1208	Video-assisted genetic counselling for hereditary Cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1209	Patient Preference for the Administration of Pelgraz by Infector (PFI) versus Needle (PFS) for the Prevention of Neutropenia in Breast Cancer Patients receiving Myelosuppressive Chemotherapy	Frauenheilkunde_751	Pfeiler Georg
FA751D1204	A double-blind, randomized, placebocontrolled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women.	Frauenheilkunde_751	Ott Johannes
FA744C0104	Biofilmbildung auf Grenz- und Oberflächen aktiver Implantate und Elektrostimulation zur Therapie von Rekurrensparesen	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider-Stickler Berit

FA731C1410	Educational Grant - Heart Failure Personal - Anstellungskosten	Herzchirurgie_732	Zimpfer Daniel
FA731C2102	Intuity Database	Herzchirurgie_732	Andreas Martin
FA731C2301	Pumpe für ECCO2R - Anteil Herzchirurgie	Herzchirurgie_732	Granegger Marcus
FA731C2301	Pumpe für ECCO2R - Anteil Herzchirurgie	Herzchirurgie_732	Granegger Marcus
FA732A0403	Formative Human Factor Study	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0502	ShuttlePump II - Safety and efficacy assessment of a novel total artificial heart	Herzchirurgie_732	Granegger Marcus
FA103A0007	Medical Neuroscience	Hirnforschung_360	Berger Johannes
FA684A0104	Evaluating glial and neuronal GFAP, MCP-1 and NfL as blood biomarkers for onset and disease severity in cerebral adrenoleukodystrophy"	Hirnforschung_360	Berger Johannes
FA711A0152	A Phase II, Open-label, Study in Subjects with BRAF V600E - Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib	Innere Medizin I_711	Preusser Matthias
FA711A0313	A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)"	Innere Medizin I_711	Burgmann Heinz

FA711A0314	Eine multizentrische, randomisierte, aktiv kontrollierte, doppelblinde Doppel-Dummy-Studie der Phase III zur Beurteilung der Wirksamkeit und Sicherheit von Maribavir im Vergleich zu Valganciclovir bei der Behandlung der Cytomegalovirusinfektion (CMV-Infektion) bei Empfängern eines hämatopoetischen Stammzelltransplantats	Innere Medizin I_711	Burgmann Heinz
FA711B0475	APHINITY - A Randomized multicener, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer	Innere Medizin I_711	Preusser Matthias
FA711B0527	PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer	Innere Medizin I_711	Preusser Matthias
FA711B0528	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Innere Medizin I_711	Preusser Matthias
FA711B0719	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for	Innere Medizin I_711	Preusser Matthias

	recurrence: A randomized phase III study		
FA711B0732	Supplementary Agreement zu: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup> Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)	Innere Medizin I_711	Preusser Matthias
FA711B0803	ABCSG 22R Quality of Life, A survey conducted on the quality of life of breast cancer patients registered in ABCSG 22R,	Innere Medizin I_711	Preusser Matthias
FA711B0912	The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	Innere Medizin I_711	Preusser Matthias
FA711B0921	CA209-650: Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer	Innere Medizin I_711	Preusser Matthias

FA711B0931	Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: A multicenter, single arm study	Innere Medizin I_711	Preusser Matthias
FA711B0985	Phase-II-Studie zu Acalabrutinib in Kombination mit Tafasitamab bei Patienten/-innen mit zuvor behandelten Lymphomen der marginalen Zone (MZL) IELSG 49	Innere Medizin I_711	Preusser Matthias
FA711B0987	An EPidEmiological, PRospective Cohort Study to Generate Real-world Evidence in Patients With HR+/HER2-Advanced Breast Cancer Treated in the First-line Setting as per Current Standard Of Care With an EndocRine-based Palbociclib CoMbination Therapy	Innere Medizin I_711	Preusser Matthias
FA711B0988	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Innere Medizin I_711	Preusser Matthias
FA711B0989	Randomisierte, multizentrische Phase III-Studie zu Milademetan versus Trabectedin bei Patienten mit dedifferenziertem Liposarkom	Innere Medizin I_711	Preusser Matthias

FA711B0990	A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy	Innere Medizin I_711	Preusser Matthias
FA711C0120	Vonicog alfa (recombinant von Willebrand factor) Treatment Outcomes in von Willebrand Disease in Selected European Countries: a Retrospective Chart Review Study	Innere Medizin I_711	Kyrle Paul Alexander
FA711C0367	24-month prospective, multicentre, non-interventional study to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A (A-SURE)	Innere Medizin I_711	Pabinger Ingrid
FA711C0666	A Multicenter, Phase III, Open-label, randomized study in relapsed/refractory patients with Chronic Lymphocytic Leukemia to evaluate the benefit of GDC-0199 (ABT-199) plus Rituximab compared with Bendamustine plus Rituximab	Innere Medizin I_711	Jäger Ulrich

FA711C0902	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0903	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0904	A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase“ - interner Studiencode CABL001J12301	Innere Medizin I_711	Valent Peter
FA711C0905	A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS 13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or	Innere Medizin I_711	Valent Peter



	hereditary thrombotic thrombocytopenic purpura)		
FA711C1007	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES-ALX0681-C302)	Innere Medizin I_711	Valent Peter
FA711C1010	Randomisierte Phase II, 2-Arm Studie bei für Transplantation ungeeignete Patienten mit neu diagnostizierten multiplen Myelom (NDMM) zum Vergleich von Carfilzomib + Thalidomid + Dexamethason (KTD) Induktionstherapie mit Carfilzomib + Lenalidomid + Dexamethason (KRD) Induktionstherapie in Bezug auf Ansprechraten und Untersuchung einer Monotherapie mit Carfilzomib (K) als Erhaltungstherapie	Innere Medizin I_711	Valent Peter
FA711C1016	Prospective, Non-Interventional Study to Evaluate the Safety and Effectiveness of OBIZUR in Real Life Practice (241501)	Innere Medizin I_711	Valent Peter

FA711C1050	Comprehensive genomic profiling and next generation functional drug screening for patients with aggressive haematological malignancies: next generation personal medicine	Innere Medizin I_711	Valent Peter
FA711C1074	Eine prospektive, randomisierte, kontrollierte, offene, multizentrische, in zwei Abschnitte gegliederte Crossover-Studie der Phase III mit einer aus einem einzigen Arm bestehenden Fortsetzung zur Beurteilung der Sicherheit und Wirksamkeit von BAX 930 (rADAMTS13) bei der prophylaktischen und Bedarfsbehandlung von Patienten mit schwerer kongenitaler thrombotisch thrombozytopenischer Purpura (cTTP, Upshaw-Schulman-Syndrom USS, hereditäre thrombotisch thrombozytopenische Purpura, hTTP)	Innere Medizin I_711	Valent Peter
FA711C1076	Deciphering resistance to anti-CTL019 CAR-T cell therapy in diffuse large B-cell lymphoma	Innere Medizin I_711	Jäger Ulrich
FA711C1081	CADENCE Registry Cold Agglutinin Disease Real World Evidence Registry	Innere Medizin I_711	Jäger Ulrich
FA711C1093	A Phase 2, open-label study to evaluate the long-term safety of oral BCX9930 in subjects with paroxysmal nocturnal hemoglobinuria (PNH)	Innere Medizin I_711	Valent Peter

FA711C1097	eSMART: Verlaufsuntersuchung von Lebensqualität bei Krebspatienten der Abteilung für Hämatologie mittels der psychoonkologischen Basisdiagnostik	Innere Medizin I_711	Valent Peter
FA711C1308	A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia	Innere Medizin I_711	Jäger Ulrich
FA711C1317	A pivotal Phase II randomized, multi- centre, open-label study to evaluate the efficacy and safety of MB- CART2019.1 compared to standard of care therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma (R-R DLBCL), who are not eligible for High Dose Chemotherapy and Autologous Stem Cell Transplantation	Innere Medizin I_711	Jäger Ulrich
FA711C1318	A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (INCB050465)	Innere Medizin I_711	Jäger Ulrich
FA711C1401	A multinational, open- label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors; Protocol ID: NN7769- 4514	Innere Medizin I_711	Ay Cihan
UE71106010	Personalkostenförderung Studieninfrastruktur	Innere Medizin I_711	Valent Peter

UE71106013	Spende der Amgen GmbH – Personalkostenförderung	Innere Medizin I_711	Pabinger Ingrid
UE71106015	Personalkostenförderung - Myelom Koordination	Innere Medizin I_711	Valent Peter
FA714B0204	NEwTON AF: Clinical Evaluation of the StablePoint Catheter and Force-Sensing System for Paroxysmal Atrial Fibrillation	Innere Medizin II_714	Stix Günter
FA714B0374	Role of DNases in therapy and diagnostics of cardiovascular diseases	Innere Medizin II_714	Lang Irene
FA714B0385	Index of microcirculatory resistance and transmural pressure	Innere Medizin II_714	Lang Irene
FA714B0386	Eine nicht-randomisierte, monozentrische, offene, zwei Perioden Studie, mit gepaartem Design zur Untersuchung der Plasmalevel Gleichgewichtskonzentration, nach Umstellung von einer 10 mg/ml Treprostinil Formulierung auf eine 20 mg/ml Treprostinil Formulierung in Patienten mit Pulmonal-arterieller Hypertension (PAH)	Innere Medizin II_714	Lang Irene
FA714B0531	Cardior	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B1520	Assessment of Myocardial Amyloid Deposition, Cardiac Function and Exercise Capacity in Patients with cardiac Transthyretin Amyloidose	Innere Medizin II_714	Kastner Johannes
FA714B1606	Nicht-invasive Gewebscharakterisierung und Denervationserfassung mittels PET-MRT bei Patienten mit Anderson Fabry Erkrankung	Innere Medizin II_714	Graf Senta
FA714B2202	Optimizing patient allocation to maximize efficacy in a TAVR program	Innere Medizin II_714	Goliasch Georg

FA714B2716	Eine Phase-1b-Studie zur Beurteilung der Sicherheit und Wirksamkeit von AMG 757 in Kombination mit AMG 404 bei Patienten mit kleinzelligem Lungenkrebs (SCLC)	Innere Medizin II_714	Bergler-Klein Jutta
FA714B2903	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in participants following an acute myocardial infarction PACIFIC-AMI	Innere Medizin II_714	Hengstenberg Christian
FA714B3109	Studie zur Krankheitslast bei ATTR-CM-Patienten und deren Betreuern // Burden of Disease (BOD) Study in ATTR-CM Patients and Caregivers	Innere Medizin II_714	Kastner Johannes
FA714B4701	Eine multizentrische, doppelblinde, dreiarmlige, placebound aktiv kontrollierte Studie der Phase II zur Beurteilung der Wirksamkeit und Sicherheit von Verinurad in Kombination mit Allopurinol bei Herzinsuffizienz mit erhaltener Ejektionsfraktion. (Amethyst)	Innere Medizin II_714	Badr Eslam Roza
FA714B4702	Einfluss der Diabetes-Medikation auf den Krankheitsverlauf in Patienten mit Herzinsuffizienz vom HFpEF-Typ	Innere Medizin II_714	Badr Eslam Roza
FA714B4702	Einfluss der Diabetes-Medikation auf den Krankheitsverlauf in Patienten mit Herzinsuffizienz vom HFpEF-Typ	Innere Medizin II_714	Badr Eslam Roza

FA714B4901	A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	Innere Medizin II_714	Kastl Stefan
FA714B4902	Eine randomisierte, doppelblinde, adaptive Phase-II/III-Studie mit GSK3359609 oder Placebo in Kombination mit Pembrolizumab zur Erstlinienbehandlung von PD-L1 positiven rezidivierten oder metastasierten Kopf- und Hals-Plattenepithelkarzinomen (INDUCE-3)I	Innere Medizin II_714	Kastl Stefan
FA714B4904	Eine Phase-Ib-Studie zur Beurteilung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von AMG 160 bei Patienten mit nicht-kleinzelligem Lungenkarzinom	Innere Medizin II_714	Kastl Stefan
FA714B4905	A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line	Innere Medizin II_714	Kastl Stefan

	metastatic pancreatic ductal adenocarcinoma (mPDAC)		
FA714B5401	COVID-19 Infektion und chronisch thromboembolische Lungenerkrankung (chronisch thromboembolische pulmonale Hypertension, CTEPH und chronisch thromboembolische Erkrankung, CTEPD) - Pilotstudie	Innere Medizin II_714	Skoro-Sajer Nika
FA714C0710	Prospective, multicentre single-arm Post-Market Clinical Follow-up (PMCF) study to evaluate safety and performance of the BeYond Venous Self-Expanding Stent	Innere Medizin II_714	Schlager Oliver
FA714D0802	IMPALLA - IMPAct of ArtiQ.PFT, an artificial intelligence bASed data interpretation tool, on improving the diagnosis and referral process for ILD patients.	Innere Medizin II_714	Gompelmann Daniela
UE71406016	Durchführung einer retrospektiven multizentrischen Erhebung zur Indikation und Wirksamkeit von Cangrelor bei perkutanter Koronarintervention	Innere Medizin II_714	Siller-Matula Jolanta
UE71406017	Complex and High risk Coronary Intervention Procedure	Innere Medizin II_714	Niessner Alexander
FA716B1501	THE ROLE OF LEPTIN IN REGULATING HEPATIC LIPID METABOLISM IN LIPODYSTROPHY	Innere Medizin III_716	Scherer Thomas

FA716B1703	#backtoclinic	Innere Medizin III_716	Hufgard-Leitner Miriam Kristin
FA716C1021	Recombinant SARS-CoV-2-antibodies in kidney transplant recipients without neutralizing antibody response following full vaccination	Innere Medizin III_716	Oberbauer Rainer
FA716D0719	Assessment of Guselkumab (Tremfya®) and IL-17 Inhibitor Therapies in Patients with Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study; CNTO1959PSA4001	Innere Medizin III_716	Scheinecker Clemens
FA716D0810	Eine Populations-basierte prospektive klinische Studie zur Effektivität und Sicherheit der Covid-19 Auffrischungsimpfung	Innere Medizin III_716	Aletaha Daniel
FA716E0843	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Innere Medizin III_716	Trauner Michael
FA716E0913	INTIMIC - Dietary Modulation of intestinal microbiota as Trigger of liver health: role of bile acids (Di Mi Liv)	Innere Medizin III_716	Trauner Michael
FA716E0939	Targeting mucosal biofilms in patients with gastrointestinal disorders	Innere Medizin III_716	Trauner Michael
FA716E0943	Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality	Innere Medizin III_716	Trauner Michael



FA716E1004	A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis	Innere Medizin III_716	Trauner Michael
FA716E1005	Prospective, non-interventional, observational study in patients with IBD receiving IV or SC vedolizumab therapy to observe route of administration choices and outcomes (VARIETY-AUT)	Innere Medizin III_716	Trauner Michael
FA716E1007	Role of Bile Acid Signaling in Liver Sinusoidal endothelial cell-mediated liver regeneration	Innere Medizin III_716	Trauner Michael
FA781B1402	Jeffrey Modell Immunodeficiency Center @ MedUni Vienna	Kinder- und Jugendheilkunde_781	Förster-Waldl Elisabeth
FA781B1403	Repositioning to tackle COVID-19	Kinder- und Jugendheilkunde_781	Förster-Waldl Elisabeth
FA781B1503	EU H2020 Effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO-trial)	Kinder- und Jugendheilkunde_781	Klebermaß-Schrehof Katrin
FA781B2702	MAIA: Erforschung der Praxistauglichkeit einer ARS-Lösung (Automatic Speech Recognition) für die Dokumentation im Gesundheitssystem	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B2901	MAIA-Entlassungsplattform	Kinder- und Jugendheilkunde_781	Bibl Katharina
FA781B3201	Dissecting the Pathogenic mechanisms in central nervous system high-grade neuroepithelial tumors	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon

	with BCOR-alteration (CNS HGNET-BCOR)		
FA781B3501	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen – Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR Epilepsiesyndrome an der Medizinischen Universität Wien	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781B3502	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen – Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR Epilepsiesyndrome an der Medizinischen Universität Wien	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781D0603	Erstellung einer internetbasierten Informationsplattform für Kinderarzneimittel	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0610	Retrospektive Datenerfassung für die Feasibility einer zukünftigen Studie bei Kindern bis 18 Jahre mit Diagnose eines arteriellen ischämischen Infarkts oder Covert Brain Infarkts	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781F0115	Nationale, multizentrische Dokumentation der Therapie mit lang wirksamen Wachstumshormonen und für Noonan Syndrom	Kinder- und Jugendheilkunde_781	Häusler Gabriele
FA781F0207	ALLEVIATE - A novel strategy for food allergy prevention and treatment	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt

FA781F0208	Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei Cystischer Fibrose	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0209	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group, Outpatient Stuy Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate to Severe Atopic Dermatitis	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F1011	WAYLIVRA Post-Authorisation Safety Study (PASS) and Product Registry	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1012	A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1102	Modellierung der Mechanismen von Corpus Callosum assoziierten Erkrankung in zerebralen Organoiden	Kinder- und Jugendheilkunde_781	Seidl Rainer
FA781F1302	Eine offene Studie der Phase III zur Beurteilung der langfristigen Sicherheit und Wirksamkeit der VX 445 Kombinationstherapie bei Patienten mit zystischer Fibrose, die homozygot oder heterozygot für die F508del-Mutation sind	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt

FA781F1701	CBAF312D2301: Eine 2-jährige, randomisierte, dreiarmlige, doppelblinde Nichtunterlegenheitsstudie zum Vergleich der Wirksamkeit und Sicherheit von Ofatumumab und Siponimod gegenüber Fingolimod bei pädiatrischen Patienten mit Multipler Sklerose, gefolgt von einer offenen Verlängerung	Kinder- und Jugendheilkunde_781	Breu Markus
UE78106012	Neuropsychologische und sozioemotionale Aspekte von Neurofibromatose differenzierter erforschen	Kinder- und Jugendheilkunde_781	Pletschko Thomas
UE78106022	Mein Logbuch – ich kenne mich aus	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa
FA729A0163	Pharmacokinetic Lab Analysis of Prasugrel and Ticagrelor	Klinische Pharmakologie_729	Jilma Bernd
FA729A0165	Phase 1 Clinical Trial of the BioMed rSEB Variant Vaccine in Healthy Adults	Klinische Pharmakologie_729	Jilma Bernd
FA729A0257	Explorative, retrospektive data analysis: Longitudinal course of pharmacotherapy and health care utilization in patients with Asthma using SABA as-needed versus ICS-based asthma treatment in BURGenland	Klinische Pharmakologie_729	Wolzt Michael
FA729A0259	A multi-center, randomized, placebo-controlled, double-blind, dose-finding clinical trial investigating the short-term relief of symptoms of acute pharyngitis such as throat soreness pain and difficulty to swallow by treatment with three different doses of	Klinische Pharmakologie_729	Wolzt Michael

	MYRAMISTIN™ oromucosal spray		
FA729A0737	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with Non-Small Cell Lung Cancer	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A0738	A placebo-controlled, double-masked phase-1 study in healthy subjects investigating the safety and tolerability of laquinimod eye drops	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A0739	Assessment of safety and tolerability of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A1026	PhD Programm im Bereich "Preclinical and Clinical Research for Drug Development"	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1310	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease	Klinische Pharmakologie_729	Schmidl Doreen
FA729A1402	"PET/MR imaging to assess the role of membrane transporters in pulmonary disposition of inhaled drugs	Klinische Pharmakologie_729	Langer Claus Oliver

FA729A1404	Quantitative evaluation of the brain distribution and pharmacokinetics of isavuconazole using positron emission tomography (PET) imaging	Klinische Pharmakologie_729	Langer Claus Oliver
FA712A1104	Albuplatin	Krebsforschung_712	Heffeter Petra
FA712A1501	International PhD program in Translational Oncology	Krebsforschung_712	Szakacs Gergely
FA712A1801	Innate immune reprogramming to overcome therapy resistance in high-risk colorectal cancer	Krebsforschung_712	Herndler-Brandstetter Dietmar
FA793A0334	SHP 677	Labormedizin_793	Quehenberger Peter
FA793A0336	cobas t711-RD004741	Labormedizin_793	Quehenberger Peter
FA793A0337	Baxalta field study	Labormedizin_793	Quehenberger Peter
FA793A0338	TAK-577, Analytical Reports	Labormedizin_793	Quehenberger Peter
FA793A0807	Modulation von oxidativem Stress bei Stoffwechselerkrankungen	Labormedizin_793	Binder Christoph
FA793A0904	Österreichisches Schulstandortmonitoring	Labormedizin_793	Esterbauer Harald
FA793A1009	Targeting TGF superfamily using Acceleron Pharma compounds in the Fra-2 transgenic mouse model of multiorgan fibrosis	Labormedizin_793	Wagner Erwin Friedrich
FA793A2502	Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn's Disease	Labormedizin_793	Schweiger Christian
FA793B0117	Additional Testing for the Clinical Performance Evaluation of Sensititre TM Susceptibility YeastOne TM Plates	Labormedizin_793	Willinger Birgit
FA793B0118	Sammlung und Analyse von Daten antifungaler Resistenzen von Hefepilzen aus klinisch relevantem Untersuchungsmaterial für	Labormedizin_793	Willinger Birgit

	die Berichtsjahre 2020-2023		
FA793B0119	PEG Resistenzstudie 2019	Labormedizin_793	Willinger Birgit
FA103A0008	Molecular and Cellular Control of Tissue Homeostasis in Health and Disease - TissueHome	Medizinische Biochemie_305	Kuchler Karl
FA616A0402	EU H2020 The Nuclear Pore Basket – Functional Architecture of a Membrane Remodeling Machine	Medizinische Biochemie_305	Köhler Alwin
FA616A0701	MANufacturing of TUmour-REactive Natural Killer cells — MATURE-NK	Medizinische Biochemie_305	Von Haeseler Arndt
FA616A0902	ELLIPSE - Liquid-liquid phase separation in biology	Medizinische Biochemie_305	Karagöz Gülsün Elif
CD10260501	CD Labor für innovative optische Bildgebung und deren Translation in die Medizin	Medizinische Physik und Biomedizinische Technik_340	Leitgeb Rainer
CD10260504	Schalllabor für die Entwicklung der nächsten Generation von Ultraschallgeräten	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A0908	Evaluierung eines mobilen EKG-Systems zur Erkennung von Vorhofflimmern	Medizinische Physik und Biomedizinische Technik_340	Rafolt Dietmar
FA605A1802	EU H2020 Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease	Medizinische Physik und Biomedizinische Technik_340	Leitgeb Rainer
FA602A0108	Robotic ePartner for Memory INnovative activation of People with Dementia	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA602A0119	Pilotierung von PCR-Gurgeltests in Schulen und Erarbeitung eines Implementierungskonzepts	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja

FA660A1204	Optimal gender-specific treatment paths on healthcare multiplex networks	Medizinische Statistik, Informatik und Intelligente Systeme_303	Klimek Peter
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Medizinische Statistik, Informatik und Intelligente Systeme_303	Graf Alexandra
FA736A0502	Explorative Erforschung von miRNA-basierten Gerinnungsbiomarkern bei Glioblastompatienten	Neurochirurgie_736	Widhalm Georg
FA736A0702	LITT - Therapie in der Neurochirurgie für Epilepsiechirurgie	Neurochirurgie_736	Rössler Karl
FA736A0801	Evaluation of Sutability of Cold Ablation Robot Guided Laser Osteotomy for Stereoelectroencephalography (SEEG) Surgical Procedures in Sheep	Neurochirurgie_736	Rössler Karl
FA761A1139	A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension	Neurologie_761	Berger Thomas
FA761A1140	A multicenter open-label randomized Phase II study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma, who are not eligible for High Dose therapy and Autologous Stem Cell Transplantation	Neurologie_761	Berger Thomas



FA761A1141	Endoxaban for intracranial hemorrhage survivors with atrial fibrillation	Neurologie_761	Berger Thomas
UE76106006	Nicht-interventionelle Studie der ÖKSG: Monoklonale Antikörper zur Migräneprophylaxe	Neurologie_761	Berger Thomas
FA737A0704	Eine randomisierte, placebokontrollierte, Studienteilnehmer- und Prüfarzt-verblindete Studie zur Untersuchung der Sicherheit, Verträglichkeit und vorläufigen Wirksamkeit einer 8-wöchigen Behandlung mit intraartikulärem LRX712 zur Regenerierung von Gelenkknorpel bei Patienten mit leichter/mittelschwerer Kniearthrose.	Orthopädie und Unfallchirurgie_739	Chiari Catharina
FA737B0201	In-vivo Testung einer magnesiumbasierten, intramedullären Spannosteosynthese im Kaninchenmodell	Orthopädie und Unfallchirurgie_739	Hajdu Stefan
FA681A0104	Der Eisenmetabolismus der humanen Plazenta	Pathobiochemie und Genetik_306	Gundacker Claudia
FA791A1021	The purpose of the grant is to support the Banff Working Group for TMA in renal TX	Pathologie_791	Kozakowski Nicolas
FA791A1021	The purpose of the grant is to support the Banff Working Group for TMA in renal TX	Pathologie_791	Kozakowski Nicolas
FA791A1024	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma (RELATIVITY 098)	Pathologie_791	Kain Renate

FA791A1107	Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT) - Zentrum Prof. Jäger	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1115	"A phase I/II study of 177Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed non-Hodgkin lymphoma" Zentrum Prof. Raderer"	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1148	A pivotal Phase II randomized, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma (R-R DLBCL)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1427	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)	Pathologie_791	Haitel Andrea

FA791A1629	Impassion030- A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/Taxane-based CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE NEGATIVE BREAST CANCER	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1630	Impassion030- A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/Taxane-based CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE NEGATIVE BREAST CANCER	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1635	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 + CDK4/6 Inhibitor vs Continuing AI + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with ctDNA Detectable ESR1 Mutation Without Disease Progression During 1L Treatment (SERENA-6)	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A1636	Eine randomisierte, multizentrische, doppelblinde Phase-3-Studie zu AZD9833 (oraler SERD) plus Palbociclib im Vergleich zu Anastrozol plus Palbociclib für die Behandlung von Patienten mit Östrogenrezeptor-positivem, HER2-negativem fortgeschrittenen Mammakarzinom, die bisher keine systemische Behandlung der fortgeschrittenen Erkrankung erhalten haben (SERENA-4)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1909	A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Pathologie_791	Geleff Silvana
FA791A2605	“A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)”	Pathologie_791	Geleff Silvana
FA791A2606	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG160 in	Pathologie_791	Geleff Silvana

	Subjects with Non-Small Cell Lung Cancer		
FA791A3701	A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma	Pathologie_791	Amann Gabriele
FA791A3801	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Pathologie_791	Regele Heinz
FA623A0226	Serological analysis of patient samples from Hervaxx Clinical Trial Phase 2	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0801	Vector-borne diseases in den Einsatzgebieten des Österreichischen Bundesheeres: Kosovo und Bosnien und Herzegowina (BIH)	Pathophysiologie, Infektiologie und Immunologie_370	Kniha Edwin
FA644A0407	FUTURE DANUBE – Predicting future trends in health-related microbiological water quality of rivers in a vastly changing world	Pathophysiologie, Infektiologie und Immunologie_370	Sommer Regina
FA644A0506	MultiSense Aqua - Automated Online Flow Cytometry for Real-time Monitoring of Bacteria and Particles in Drinking Water	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A0507	An innovative strategy for the quantification and prediction of toxigenic and non-toxigenic Vibrio	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander

	cholerae in environmental water resources		
FA648A0309	Milchnahrung zur Allergieprävention im Säuglingsalter - Biochemische und immunologische Charakterisierung der Hipp-HA-Nahrung	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0310	The library of allergenic molecules	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0314	Unrestricted grant Agreement R. Valenta	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0909	Can Chinese herbal medicine play a role for preventing and treating COVID-19 in Europe?	Pathophysiologie, Infektiologie und Immunologie_370	Ma Yan
FA648A1709	Evaluierung des Zusammenhangs zwischen dem chronischem Erschöpfungssyndrom und Immundefizienzen mit Auswirkung auf die mukosale Barrierefunktionen	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Eisenhuber Eva
FA648A2401	Measurement of antibodies against SARS-CoV-2 blocking RBD-ACE2 interaction, and determination of specific AB-isotypes of vaccinated animals	Pathophysiologie, Infektiologie und Immunologie_370	Garib Viktoriya
UE64806004	Mouse models of Altrenaria allergy for DARC project	Pathophysiologie, Infektiologie und Immunologie_370	Jensen-Jarolim Erika
UE72606002	Similarities and differences between responses to epidural versus whole body non-invasive neuromodulation with focus to pain treatment	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Crevenna Richard

FA621A0601	Zusammenarbeitsvereinbarung "Apeiron Biologics AG"	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA621A0801	Control of beta cell function and survival by RYR2-mediated calcium signals	Physiologie und Pharmakologie_350	Slak Rupnik Marjan
FA625A0904	Platelet function and growth factor analysis	Physiologie und Pharmakologie_350	Assinger Alice
FA763B0444	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar Disorder Who are Early in their Illness" or "A Phase 3 Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder	Psychiatrie und Psychotherapie_763	Frey Richard
FA763B0444	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar Disorder Who are Early in their Illness" or "A Phase 3 Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder	Psychiatrie und Psychotherapie_763	Frey Richard

FA763B0444	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar Disorder Who are Early in their Illness” or “A Phase 3 Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder	Psychiatrie und Psychotherapie_763	Frey Richard
FA763C0701	Thiaminsubstitution bei Alkoholabhängigkeit: Evaluierung aktueller Behandlungsstandards	Psychiatrie und Psychotherapie_763	Amering Michaela
FA636A0602	National Healthcare Systems Changes and Challenges - Access, Inequity and Socio-Economic Inequality, a Comparison between Kenya and Zambia	Public Health_380	Jirovsky-Platter Elena
FA638A0401	Integrating Environment and Health Research: a Vision for the EU	Public Health_380	Schernhammer Eva
FA638A0402	Development and evaluation of a web-based diet quality screener for vegans	Public Health_380	Schernhammer Eva
FA646A0301	A Global Social Sciences Network for Infectious Threats and Antimicrobial Resistance	Public Health_380	Kutalek Ruth
FA646A0401	Media Campaigns to Prevent Suicide: Oregon media project	Public Health_380	Niederkrotenthaler Thomas
FA646A1001	Evaluierungs- und Analysestudie im Rahmen des betrieblichen Gesundheitsmanagements bei Deloitte Österreich	Public Health_380	Hoffmann Kathryn
FA646A1101	Gesund fürs Leben	Public Health_380	Haider Sandra



FA647A0117	Future Capacity - Social vulnerability and adaptive capacity to risks from the impacts of future heat waves and air pollution	Public Health_380	Moshammer Hanns
FA647A0804	Making Green Inclusive. Ecosystem Services, Health Impact Assessment and Participative Scenarios	Public Health_380	Haluza Daniela
UE64606004	Nahda University of Beni Suef (NUB)	Public Health_380	Rieder Anita
FA771B0828	A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0878	A randomized, double-blind, dose-ranging, placebo controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC)	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0879	Copanlisib and Rituximab in Marginal Zone Lymphoma Patients	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B1303	A phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771D0321	Protokolloptimierungen und Standardisierung am NAEOTOM Alpha	Radiologie und Nuklearmedizin_771	Loewe Christian

FA771D0527	The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0902	A Phase 1/2, Baseline-controlled, Non-randomised, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry disease (MARVEL 1)	Radiologie und Nuklearmedizin_771	Beitzke Dietrich
FA771E0213	Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant	Radiologie und Nuklearmedizin_771	Kainberger Franz
FA771E0214	An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome	Radiologie und Nuklearmedizin_771	Kainberger Franz
FA771E0506	Machine Learning for Phenotype Identification and Prediction	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0506	Machine Learning for Phenotype Identification and Prediction	Radiologie und Nuklearmedizin_771	Langs Georg
FA771G0239	A trial investigating the effect of semaglutide on atherosclerosis in patients with cardiovascular disease and type 2 diabetes	Radiologie und Nuklearmedizin_771	Hacker Marcus

FA771G0264	A GLP-1 receptor PET imaging add-on study within the Ver-A-T1D trial investigating the effects of Verapamil or placebo on beta cell mass (Image-Ver-A-T1D)	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA670F0204	Effects of one-piece individual abutment on peri-implant soft tissue and bone level: A fully digital workflow	Universitätszahnklinik Wien GmbH_991	Rausch-Fan Xiaohui
FA670F0204	Effects of one-piece individual abutment on peri-implant soft tissue and bone level: A fully digital workflow	Universitätszahnklinik Wien GmbH_991	Rausch-Fan Xiaohui
FA670D0301	Randomisierte, placebokontrollierte, doppelblinde, multizentrische Parallelgruppenstudie der Phase III zur Beurteilung der Hemmung der Plaque-Neubildung durch eine 0,1% Octenidin Mundspüllösung im Vergleich zu Placebo bei Personen mit einem Gingivitis Index kleiner gleich 1,5	Universitätszahnklinik_670	Laky Markus
FA670F0301	Initial adhesion and proliferation of gingival fibroblasts on dental implants	Universitätszahnklinik_670	Andrukhov Oleh
FA743A0109	Knochen- und immunologische Biomarker bei Patienten mit kastrationsresistentem Prostatakarzinom (CRPC) unter Therapie mit Radium-223 - Eine retrospektive Analyse	Urologie_743	Kramer Gero

FA743A0264	Sunrise-2, A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy	Urologie_743	Shariat Shahrokh
FA690A0704	Überwachung der Respiratorischen Rynzytial Viren in Österreich durch das Diagnostische Influenza Netzwerk Österreich	Virologie_307	Redlberger-Fritz Monika
FA690A0705	Epidemiological pattern of RSV circulation during and after SARS-CoV-2 pandemic, and analyses of the annual RSV epidemiology including viral co-infections	Virologie_307	Redlberger-Fritz Monika

Markus Müller

Rektor